The Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD has been funding the development of novel RNA-based therapeutic concepts for two years now. The collaborating researchers used bioinformatics-based prediction of RNA targets in fibrosis to identify novel molecular effectors. In subsequent in-vitro and ex-vivo studies, they investigated their functional impact by means of what is known as siRNA molecules. Packaging of the siRNA-based agent in particular will be further explored in upcoming studies, also in cooperation with other Fraunhofer institutes. The researchers are making use of a variety of innovative technologies here, from lipid-based nanoparticles and liposomes to silica gel particles.